Appropriate timing schedule for intravitreal anti-VEGF injection as adjuvant therapy before pars-plana vitrectomy in proliferative diabetic retinopathy, a meta analysis

References

• Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88. doi: 10.1038/nrendo.2017.151
   PubMed Web of Science ®Google Scholar
• Chen HJ, Wang CG, Dou HL, et al. Effect of intravitreal ranibizumab pretreatment on vitrectomy in young patients with proliferative diabetic retinopathy. Ann Palliat Med. 2020;9(1):82–89. doi: 10.21037/apm.2020.01.10
   PubMed Web of Science ®Google Scholar
• Guan J, Cai N, Liu LM, et al. Ranibizumab pretreatment in vitrectomy with internal limiting membrane peeling on diabetic macular edema in severe proliferative diabetic retinopathy. Diabetes Ther. 2020;11(6):1397–1406. doi: 10.1007/s13300-020-00822-0
   PubMed Web of Science ®Google Scholar
• Bandello F, Parodi MB, Lanzetta P, et al. Diabetic macular edema. Macular Edema. 2017;58:102–138.
   PubMedGoogle Scholar
• El Rami H, Barham R, Sun JK, et al. Evidence-based treatment of diabetic retinopathy. In: Semin Ophthalmol. (Vol. 32, no. 1, pp. 67–74). Taylor & Francis; 2017. doi: 10.1080/08820538.2016.1228397
   Google Scholar
• Antoszyk AN, Glassman AR, Beaulieu WT, et al. Effect of IntravitreoUs aflibercept vs vitrectomy with panretinal photocoagulation on visual acuity in patients with vitreous hemorrhage from proliferative diabetic retinopathy: A randomized clinical trial. JAMA. 2020;324(23):2383–2395. doi: 10.1001/jama.2020.23027
   PubMed Web of Science ®Google Scholar
• Yang K-B, Zhang H, Li S-J, et al. Conbercept and ranibizumab pretreatments in vitrectomy with silicone oil infusion for severe diabetic retinopathy. J Ocul Pharmacol Ther. 2019;35(3):161–167. doi: 10.1089/jop.2018.0093
   PubMed Web of Science ®Google Scholar
• Gao S, Lin Z, Shen X. Anti-vascular endothelial growth factor therapy as an alternative or adjunct to pan-retinal photocoagulation in treating proliferative diabetic retinopathy: meta-analysis of randomized trials. Front Pharmacol. 2020;11:849. doi: 10.3389/fphar.2020.00849
   PubMed Web of Science ®Google Scholar
• Xu W, Cheng W, Yao Y, et al. PreoperaTive intravitreal conbercept facilitates vitrectomy in proliferative diabetic retinopathy: Is attention required for the fellow eye? J Ophthalmol. 2019;2019:1–6. doi: 10.1155/2019/2923950
   Web of Science ®Google Scholar
• Feng J, Li B, Wen J, et al. Preoperative timing of intravitreal bevacizumab injection for proliferative diabetic retinopathy patients. Ophthalmic Res. 2018;60(4):250–257. doi: 10.1159/000493640
   PubMed Web of Science ®Google Scholar
• Egger M, Davey-Smith G, Altman D. Systematic reviews in health care: meta-analysis in context. John Wiley & Sons; 2008.
   Google Scholar
• Moons KG, de Groot JA, Bouwmeester W, et al. Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist. PLOS Med. 2014;11(10):e1001744. doi: 10.1371/journal.pmed.1001744
   PubMed Web of Science ®Google Scholar
• Li S, Yang Y, Zou J, et al. The efficacy and safety of intravitreal injection of Ranibizumab as pre-treatment for vitrectomy in proliferative diabetic retinopathy with vitreous hemorrhage. BMC Ophthalmol. 2022;22(1):1–9. doi: 10.1186/s12886-022-02303-3
   PubMed Web of Science ®Google Scholar
• Wang Q, Cai H, Xu D, et al. Pars plana vitrectomy assisted by intravitreal injection of conbercept enhances the therapeutic effect and quality of life in patients with severe proliferative diabetic retinopathy. Am J Transl Res. 2022;14(2):1324.
   PubMed Web of Science ®Google Scholar
• Takayama K, Someya H, Yokoyama H, et al. Potential bias of preoperative intravitreal anti-VEGF injection for complications of proliferative diabetic retinopathy. PLoS One. 2021;16(10):e0258415. doi: 10.1371/journal.pone.0258415
   PubMed Web of Science ®Google Scholar
• Li B, Li MD, Ye JJ, et al. Vascular endothelial growth factor concentration in vitreous humor of patients with severe proliferative diabetic retinopathy after intravitreal injection of conbercept as an adjunctive therapy for vitrectomy. Chin Med J. 2020;133(6):664–669. doi: 10.1097/CM9.0000000000000687
   PubMed Web of Science ®Google Scholar
• Gao S, Lin Z, Chen Y, et al. Intravitreal conbercept injection as an adjuvant in vitrectomy with silicone oil infusion for severe proliferative diabetic retinopathy. J Ocul Pharmacol Ther. 2020;36(5):304–310. doi: 10.1089/jop.2019.0149
   PubMed Web of Science ®Google Scholar
• Aleman I, Velazquez JC, Rush SW, et al. Ziv-aflibercept versus bevacizumab administration prior to diabetic vitrectomy: a randomised and controlled trial. Br J Ophthalmol. 2019;103(12):1740–1746. doi: 10.1136/bjophthalmol-2018-313313
   PubMed Web of Science ®Google Scholar
• Arevalo JF, Lasave AF, Kozak I, et al. Preoperative bevacizumab for tractional retinal detachment in proliferative diabetic retinopathy: A prospective randomized clinical trial. Am J Ophthalmol. 2019;207:279–287. doi: 10.1016/j.ajo.2019.05.007
   PubMed Web of Science ®Google Scholar
• Lu Q, Lu L, Chen B, et al. Efficacy comparison of intravitreal injections of conbercept and ranibizumab for severe proliferative diabetic retinopathy. Can J Ophthalmol. 2019;54(3):291–296. doi: 10.1016/j.jcjo.2018.06.010
   PubMed Web of Science ®Google Scholar
• Cui J, Chen H, Lu H, et al. Efficacy and safety of intravitreal conbercept, ranibizumab, and triamcinolone on 23-Gauge vitrectomy for patients with proliferative diabetic retinopathy. J Ophthalmol. 2018 25;2018:1–11. doi: 10.1155/2018/4927259
   Web of Science ®Google Scholar
• Mao JB, Wu HF, Chen YQ, et al. Effect of intravitreal conbercept treatment before vitrectomy in proliferative diabetic retinopathy. Int J Ophthalmol. 2018;11(7):1217–1221. doi: 10.18240/ijo.2018.07.23
   PubMed Web of Science ®Google Scholar
• Velazquez JC, Aleman I, Rush SW, et al. Bevacizumab before diabetic vitrectomy: a clinical trial assessing 3 dosing amounts. Ophthalmol Retina. 2018;2(10):1010–1020. doi: 10.1016/j.oret.2018.04.014
   PubMedGoogle Scholar
• Zhou J, Liu Z, Chen M, et al. Concentrations of VEGF and PlGF decrease in eyes after intravitreal conbercept injection. Diabetes Ther. 2018;9(6):2393–2398. doi: 10.1007/s13300-018-0527-9
   PubMed Web of Science ®Google Scholar
• Castillo J, Aleman I, Rush SW, et al. Preoperative bevacizumab administration in proliferative diabetic retinopathy patients undergoing vitrectomy: A randomized and controlled trial comparing interval variation. Am J Ophthalmol. 2017;183:1–10. doi: 10.1016/j.ajo.2017.08.013
   PubMed Web of Science ®Google Scholar
• Comyn O, Wickham L, Charteris D, et al. Ranibizumab pretreatment in diabetic vitrectomy: a pilot randomised controlled trial (the RaDiVit study). Eye. 2017;31(9):1253–1258. doi: 10.1038/eye.2017.75
   PubMed Web of Science ®Google Scholar
• Su L, Ren X, Wei H, et al. Intravitreal conbercept (KH902) for surgical treatment of severe proliferative diabetic retinopathy. Retina. 2016;36(5):938–943. doi: 10.1097/IAE.0000000000000900
   PubMed Web of Science ®Google Scholar
• Yang X, Xu J, Wang R, et al. A randomized controlled trial of conbercept pretreatment before vitrectomy in Proliferative diabetic retinopathy. J Ophthalmol. 2016;2016:2473234. DOI:10.1155/2016/2473234
   PubMed Web of Science ®Google Scholar
• Manabe A, Shimada H, Hattori T, et al. Randomized controlled study of intravitreal bevacizumab 0.16 mg injected one day before surgery for proliferative diabetic retinopathy. Retina. 2015;35(9):1800–1807. doi: 10.1097/IAE.0000000000000577
   PubMed Web of Science ®Google Scholar
• Li J-K, Wei F, Jin X-H, et al. Changes in vitreous VEGF, bFGF and fibrosis in proliferative diabetic retinopathy after intravitreal bevacizumab. Int J Ophthalmol. 2015;8(6):1202. doi: 10.3980/j.issn.2222-3959.2015.06.22
   PubMed Web of Science ®Google Scholar
• Pakzad-Vaezi K, Albiani DA, Kirker AW, et al. A randomized study comparing the efficacy of bevacizumab and ranibizumab as pre-treatment for pars plana vitrectomy in proliferative diabetic retinopathy. Ophthalmic Surg Lasers Imaging Retina. 2014;45(6):521–524. doi: 10.3928/23258160-20141118-06
   PubMed Web of Science ®Google Scholar
• Berk Ergun S, Toklu Y, Cakmak HB, et al. The effect of intravitreal bevacizumab as a pretreatment of vitrectomy for diabetic vitreous hemorrhage on recurrent hemorrhage. Semin Ophthalmol. 2014;30(3):177–180. doi: 10.3109/08820538.2013.835847
   PubMed Web of Science ®Google Scholar
• Zaman Y, A-U R, Memon AF. Intravitreal Avastin as an adjunct in patients with proliferative diabetic retinopathy undergoing pars plana vitrectomy. Pak J Med Sci. 2013;29(2):590. doi: 10.12669/pjms.292.3044
   PubMed Web of Science ®Google Scholar
• Demir M, Oba E, Can E, et al. Effect of bevacizumab injection before vitrectomy on intravitreal hemorrhage in pseudophakic patients with proliferative diabetic retinopathy. Ophthalmol Eye Dis. 2013;5:OED. S12352. doi: 10.4137/OED.S12352
   PubMedGoogle Scholar
• Sato T, S-I M, Bando H, et al. Early vitreous hemorrhage after vitrectomy with preoperative intravitreal bevacizumab for proliferative diabetic retinopathy. Middle East Afr J Ophthalmol. 2013;20(1):51. doi: 10.4103/0974-9233.106387
   PubMedGoogle Scholar
• Gupta A, Bansal R, Gupta V, et al. Six-month visual outcome after pars plana vitrectomy in proliferative diabetic retinopathy with or without a single preoperative injection of intravitreal bevacizumab. Int Ophthalmol. 2012;32(2):135–144. doi: 10.1007/s10792-012-9541-5
   PubMed Web of Science ®Google Scholar
• Pokroy R, Desai U, Du E, et al. Bevacizumab prior to vitrectomy for diabetic traction retinal detachment. Eye. 2011;25(8):989–997. doi: 10.1038/eye.2011.149
   PubMed Web of Science ®Google Scholar
• Jeon S, Lee WK. Intravitreal bevacizumab increases intraocular interleukin-6 levels at 1 day after injection in patients with proliferative diabetic retinopathy. Cytokine. 2012;60(2):535–539. doi: 10.1016/j.cyto.2012.07.005
   PubMed Web of Science ®Google Scholar
• Han X-X, Guo C-M, Li Y, et al. Effects of bevacizumab on the neovascular membrane of proliferative diabetic retinopathy: reduction of endothelial cells and expressions of VEGF and HIF-1α. Mol Vis. 2012;18:1.
   PubMed Web of Science ®Google Scholar
• Ahn J, Woo SJ, Chung H, et al. The effect of adjunctive intravitreal bevacizumab for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy. Ophthalmol. 2011;118(11):2218–2226. doi: 10.1016/j.ophtha.2011.03.036
   PubMed Web of Science ®Google Scholar
• Farahvash M-S, Majidi AR, Roohipoor R, et al. Preoperative injection of intravitreal bevacizumab in dense diabetic vitreous hemorrhage. Retina. 2011;31(7):1254–1260. doi: 10.1097/IAE.0b013e31820a68e5
   PubMed Web of Science ®Google Scholar
• Di Lauro R, De Ruggiero P, Di Lauro R, et al. Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. Graefes Arc Clin Exp Ophthalmol. 2010;248(6):785–791. doi: 10.1007/s00417-010-1303-3
   PubMed Web of Science ®Google Scholar
• SEH-D M, Nuñez-Solorio SM. Experience with intravitreal bevacizumab as a preoperative adjunct in 23-G vitrectomy for advanced proliferative diabetic retinopathy. Eur J Ophthalmol. 2010;20(6):1047–1052. doi: 10.1177/112067211002000604
   PubMed Web of Science ®Google Scholar
• Li C-R, Sun S-G, Hong W. Effect of intravitreal bevacizumab injection before vitrectomy on proliferative diabetic retinopathy. Int J Ophthalmol. 2010;3(3):261.
   PubMed Web of Science ®Google Scholar
• Hattori T, Shimada H, Nakashizuka H, et al. Dose of intravitreal bevacizumab (Avastin) used as preoperative adjunct therapy for proliferative diabetic retinopathy. Retina. 2010;30(5):761–764. doi: 10.1097/IAE.0b013e3181c70168
   PubMed Web of Science ®Google Scholar
• Modarres M, Nazari H, Ghasemi Falavarjani K, et al. Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy. Eur J Ophthalmol. 2009;19(5):848–852. doi: 10.1177/112067210901900526
   PubMed Web of Science ®Google Scholar
• Yeh P-T, Yang C-M, Lin Y-C, et al. Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy. Retina. 2009;29(6):768–774. doi: 10.1097/IAE.0b013e3181a3b7ef
   PubMed Web of Science ®Google Scholar
• Da R Lucena D, Ribeiro JA, Costa RA, et al. Intraoperative bleeding during vitrectomy for diabetic tractional retinal detachment with versus without preoperative intravitreal bevacizumab (IBeTra study). British Journal Of Ophthalmology. 2009;93(5):688–691. doi: 10.1136/bjo.2008.151233
   PubMed Web of Science ®Google Scholar
• Ahmadieh H, Shoeibi N, Entezari M, et al. Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial. Ophthalmol. 2009;116(10):1943–1948. doi: 10.1016/j.ophtha.2009.07.001
   PubMed Web of Science ®Google Scholar
• El-Batarny AM. Intravitreal bevacizumab as an adjunctive therapy before diabetic vitrectomy. Clin Ophthalmol. 2008;2(4):709. doi: 10.2147/OPTH.S3521
   PubMedGoogle Scholar
• Rizzo S, Genovesi-Ebert F, Di Bartolo E, et al. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arc Clin Exp Ophthalmol. 2008;246(6):837–842. doi: 10.1007/s00417-008-0774-y
   PubMed Web of Science ®Google Scholar
• Yang CM, Yeh PT, Yang CH, et al. Bevacizumab pretreatment and long-acting gas infusion on vitreous clear-up after diabetic vitrectomy. Am J Ophthalmol. 2008;146(2):211–217. doi: 10.1016/j.ajo.2008.04.028
   PubMed Web of Science ®Google Scholar
• Borenstein M, Hedges LV, Higgins JP, et al. A basic introduction to fixed‐effect and random‐effects models for meta‐analysis. Res Synth Methods. 2010;1(2):97–111. doi: 10.1002/jrsm.12
   PubMed Web of Science ®Google Scholar
• Li JK, Wei F, Jin XH, et al. Changes in vitreous VEGF, bFGF and fibrosis in proliferative diabetic retinopathy after intravitreal bevacizumab. Int J Ophthalmol. 2015;8(6):1202–1206. doi: 10.3980/j.issn.2222-3959.2015.06.22
   PubMed Web of Science ®Google Scholar
• Cheema RA, Mushtaq J, Al-Khars W, et al. Role of intravitreal bevacizumab (Avastin) injected at the end of diabetic vitrectomy in preventing postoperative recurrent vitreous hemorrhage. Retina. 2010;30(10):1646–1650. doi: 10.1097/IAE.0b013e3181d6def0
   PubMed Web of Science ®Google Scholar
• Park DH, Shin JP, Kim SY. Intravitreal injection of bevacizumab and triamcinolone acetonide at the end of vitrectomy for diabetic vitreous hemorrhage: a comparative study. Graefes Arc Clin Exp Ophthalmol. 2010;248(5):641–650. doi: 10.1007/s00417-009-1247-7
   PubMed Web of Science ®Google Scholar
• Zhang Z-H, Liu H-Y, Hernandez-Da Mota SE, et al. Vitrectomy with or without preoperative intravitreal bevacizumab for proliferative diabetic retinopathy: a meta-analysis of randomized controlled trials. Am J Ophthalmol. 2013;156(1):106–115. e2. doi: 10.1016/j.ajo.2013.02.008
   PubMed Web of Science ®Google Scholar